Drugs.com - Monthly Update April 2026
In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments.
- Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.
- Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.
- Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed.
- Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.
Chapters:
Follow Drugs.com:
- (00:21) - Intro
- (01:05) - Foundayo
- (01:59) - Otarmeni
- (02:55) - Idvynso
- (03:50) - Langlara
- (04:42) - Outro
Follow Drugs.com:
- X, Facebook, YouTube
- Sign up to our newsletters
- Download the app
